# US 2021/0355127 A1 · Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0355127 A1
- Document ID: US20210355127A1
- Status: Published application
- Kind: A1
- Application number: 17/237,656
- Filed: 2021-04-22
- Published: 2021-11-18
- Earliest claimed: 2015-05-04
- Assignees: AstraZeneca AB
- Applicants: Astrazeneca AB
- Inventors: Johan Olof Broddefalk; Hans Fredrik Emtenäs; Kenneth Lars Granberg; Malin Anita Lemurell; Daniel Tor Pettersen; Alleyn Thomas Plowright; Lars Johan Andreas Ulander
- Web page: https://patentgrep.com/patent/US20210355127A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/40: Acylated on said nitrogen atom
- C07D 231/44: Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D 231/50: Acylated on said nitrogen atom
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

## Claims

### Claim 1

A method of treating diseases or conditions in which inhibition of FLAP is beneficial, comprising administering to a patient in need thereof an effective amount of a compound according to Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is H, C1-C3 alkyl, halo, C1-C3 alkoxy, C1-C3 haloalkyl or C1-C3 haloalkoxy;
each of R2 and R3 is independently H, C1-C3 alkyl, C1-C3 alkoxy, —CN or halo;
R4 is H, —CH3, —CH2F, —CHF2, —CF3 or halo;
Ring A contains 2 double bonds;
each X1, X2, X3 and X4 of Ring A is independently CR5, CH, O, S, NR6 or N; wherein at least one of X1, X2, X3 and X4 in Ring A is NR6;
each R5 is optionally and independently C1-C6 alkyl, C1-C6 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, —S(O)pR7, —CN, —CONR′R″, or C3-C6 cycloalkyl;
each p is independently 0, 1 or 2;
R6 is H, —CH3 or —CH2CH3;
or wherein when X4 is CR5 and X3 is NR6, then the R5 and R6 may be taken together to form a 5 to 6-membered heterocyclyl ring fused to Ring A, which heterocyclyl may optionally contain an additional heteroatom selected from N, O and S; said fused heterocyclyl may additionally contain a carbonyl or a —S(O)2 directly adjacent to a heteroatom therein; and may be further substituted with one or two substituents selected from the group consisting of —CH3 and halo;
R7 is —CH3 or —NR′R″; and
each R′ and R″ is independently —H or —CH3;
provided that the total number of substituents on Ring A is 0, 1 or 2; and further provided that when R5 and R6 are not combined to form a heterocyclyl ring fused to Ring A, that the total number of R5 and R6 substituents which is alkyl and/or haloalkyl is 0 or 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein R4 is —H or —CH3.

### Claim 3 (depends on 1)

The method of claim 1, wherein R2 and R3 are each independently —F or —H.

### Claim 4 (depends on 1)

The method of claim 1, wherein R1 is —H.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is according to formula (II):
or a pharmaceutically acceptable salt thereof,
wherein
each X1, X2 and X4 of Ring A is independently CR5, CH, or N; wherein at least one of X1, X2 and X4 in Ring A is N; and
X3 is O, S or NR6;
or wherein when X4 is CR5 and X3 is NR6, then the R5 and R6 may be taken together to form a 5 to 6-membered heterocyclyl ring fused to Ring A, which heterocyclyl may optionally contain an additional heteroatom selected from N, O and S; said fused heterocyclyl may additionally contain a carbonyl or a —S(O)2 directly adjacent to a heteroatom therein; and may be further substituted with one or two substituents selected from the group consisting of —CH3 and halo;
and R1, R2, R4, R5 and R6 are as defined in claim 1.

### Claim 6 (depends on 1)

The method of claim 1, wherein X1 is CH or CR5, wherein R5 is as defined in claim 1.

### Claim 7 (depends on 1)

The method of claim 1, wherein X4 is CR5 wherein R5 is as defined in claim 1.

### Claim 8 (depends on 1)

The method of claim 1, wherein Ring A is an optionally and independently substituted pyrazole, triazole, oxazole, thiazole, oxadiazole or thiadiazole.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is according to formula (III):
or a pharmaceutically acceptable salt thereof; wherein:
X1 is CH or CR5;
X2 is N;
X3 is O, S, or NR6;
X4 is CH or CR5;
R2 is —H or —F;
R5 is —S(O)2NR′R″, —SO2CH3; —C(O)NR′R″, —CN, C1-C2 alkoxy, C1-C2 haloalkoxy or C1-C2 haloalkyl;
R6 is H, —CH3 or —CH2CH3;
each R′ and R″ is independently —H or —CH3;
or wherein when X4 is CR5 and X3 is NR6, then the R5 and R6 may be taken together to form a 5 to 6-membered heterocyclyl ring fused to Ring A, which heterocyclyl may optionally contain an additional heteroatom selected from N, O and S; said fused heterocyclyl may additionally contain a carbonyl or a —S(O)2 directly adjacent to a heteroatom therein; and may be further substituted with one or two substituents selected from the group consisting of —CH3 and halo;
and
R4 is as defined in claim 1.

### Claim 10 (depends on 9)

The method of claim 9, wherein one of X1 is CH, X2 is N and X3 is NR6 and R6 is as defined in claim 9.

### Claim 11 (depends on 9)

The method of claim 9, wherein X4 is CR5 and X3 is NR6 and together the R5 and R6 substituents form a 5-6 membered heterocyclyl ring fused to Ring A, to form a bicyclic ring together with ring A selected from:

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound is according to formula (IV):
or a pharmaceutically acceptable salt thereof, wherein:
X1 is CH or CR5;
R5, if present, is —CH3;
R2 is —H or —F;
R4 is —H or —CH3; and
R8 is —H or CH3.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound is according to the formula (V):
or a pharmaceutically acceptable salt thereof, wherein:
X1 is CH or CR5;
R2 is —H or —F;
R4 is —H or —CH3;
R5, if present, is —CH3; and
R6 is —H or —CH3;
provided that R5 and R6 are not both —CH3 at the same time.

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound is according to formula (VI):
or a pharmaceutically acceptable salt, wherein:
X1 is CH or CR5;
R2 is —H or —F;
R4 is —H or —CH3;
R5, if present, is —CH3; and
R6 is —H or —CH3;
provided that R5 and R6 are not both —CH3 at the same time.

### Claim 15 (depends on 1)

The method of claim 1, wherein the compound is according to formula (VII):
or a pharmaceutically acceptable salt, wherein:
one of X1 and X4 is CH, and the other is CR5;
R2 is —H or —F;
R4 is —H or —CH3;
R5 is —CH3 or C1-haloalkyl; and
R6 is —H or —CH3;
provided that the total number of R5 and R6 substituents in the A ring which is alkyl is 0 or 1.

### Claim 16

A method of treating diseases or conditions in which inhibition of FLAP is beneficial, comprising administering to a patient in need thereof an effective amount of a compound selected from the group consisting of:
Trans(+) or Trans(−) 1-Methyl-4-[({(1R,2R or 1S,2S)-2-[4-(1H-pyrazol-3-yl)benzoyl]-cyclohexyl}carbonyl)amino]-1H-pyrazole-3-carboxamide;
1-Methyl-4-[({(1R,2R)-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexyl}carbonyl)amino]-1H-pyrazole-5-carboxamide;
1-Methyl-4-[({(1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexyl}carbonyl)amino]-1H-pyrazole-5-carboxamide;
1-Methyl-4-[({(1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexyl}carbonyl)amino]-1H-pyrazole-3-carboxamide;
Trans(−) (1S,2S or 1R,2R)—N-(3-Cyano-1-methyl-1H-pyrazol-4-yl)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
Trans(+) (1R,2R or 1S,2S)—N-(3-Cyano-1-methyl-1H-pyrazol-4-yl)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(1H-pyrazol-4-yl)cyclohexanecarboxamide;
(1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide;
((1R,2R)—N-[1-Methyl-5-(methylsulfonyl)-1H-pyrazol-4-yl]-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-[3-(Difluoromethoxy)-1-methyl-1H-pyrazol-4-yl]-2-(4-(1H-pyrazol-5-yl)benzoyl)-cyclohexanecarboxamide;
(1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(1-methyl-3-sulfamoyl-1H-pyrazol-4-yl)cyclohexanecarboxamide;
(1R,2R)—N-(2,3-Dihydropyrazolo[5,1-b][1,3]oxazol-7-yl)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
Trans(−) (1R,2R or 1S,2S)—N-(3-Cyano-1-methyl-1H-pyrazol-4-yl)-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(1-methyl-5-sulfamoyl-1H-pyrazol-4-yl)cyclohexanecarboxamide;
Trans (+/−) (1R,2R and 1S,2S)—N-(5-Methoxy-1-methyl-1H-pyrazol-4-yl)-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-[5-(Difluoromethyl)-1H-pyrazol-4-yl]-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-(5-Methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-(5-Methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
Trans(−) (1R,2R or 1S,2S)—N-(5-Cyano-1-methyl-1H-pyrazol-4-yl)-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
Trans(+) (1S,2S or 1R,2R)—N-(5-Cyano-1-methyl-1H-pyrazol-4-yl)-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
1-Ethyl-4-[({(1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1H-pyrazole-5-carboxamide;
Trans(±)-N,1-Dimethyl-4-[({(1R,2R and 1S,2S)-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1H-pyrazole-3-carboxamide;
N,1-Dimethyl-4-[({(1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]-cyclohexyl}carbonyl)amino]-1H-pyrazole-5-carboxamide;
5-Methyl-4-[({(1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-cyclohexyl}carbonyl)amino]-1H-pyrazole-3-carboxamide;
4-[({(1R,2R)-2-[4-(1H-Pyrazol-5-yl)benzoyl]cyclohexyl}carbonyl)amino]-1H-pyrazole-5-carboxamide;
(1R,2R)—N-(4-Oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-[1-Methyl-5-(methylsulfamoyl)-1H-pyrazol-4-yl]-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-(1-Methyl-3-sulfamoyl-1H-pyrazol-4-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-[5-(Dimethylsulfamoyl)-1-methyl-1H-pyrazol-4-yl]-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-(2-Methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
(1R,2R)—N-(2-Methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide; and
(1R,2R)—N-[5-(Difluoromethyl)-1H-pyrazol-4-yl]-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;
Trans(±)-4-[({(1R,2R and 1S,2S)-2-[2-Chloro-4-(1H-pyrazol-5-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;
Trans(±)-4-[({(1R,2R and 1S,2S)-2-[2-Chloro-4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-cyclohexyl}carbonyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;
Trans(±)-(1R,2R and 1S,2S)—N-(5-Cyclopropyl-1-methyl-1H-1,2,3-triazol-4-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
4-[({(1R,2R or 1S,2S)-2-[2-Fluoro-4-(1H-pyrazol-5-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;
4-[({(1R,2R or 1S,2S)-2-[2-Fluoro-4-(1H-pyrazol-5-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1-methyl-1H-pyrazole-3-carboxamide;
4-[({(1R,2R or 1S,2S)-2-[2-Fluoro-4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-cyclohexyl}carbonyl)amino]-1-methyl-1H-pyrazole-3-carboxamide;
4-[({(1R,2R or 1S,2S)-2-[2-Fluoro-4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;
4-[({(1R,2R or 1S,2S)-2-[2-Fluoro-4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1H-pyrazole-5-carboxamide;
(1R,2R or 1S,2S)-2-[2-Fluoro-4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide;
4-[({(1R,2R or 1S,2S)-2-[2-Fluoro-4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1,2,5-oxadiazole-3-carboxamide;
3-[({(1R,2R or 1S,2S)-2-[2-Fluoro-4-(1H-pyrazol-5-yl)benzoyl]cyclohexyl}carbonyl)-amino]-5-methyl-1,2-oxazole-4-carboxamide;
Trans(±)-1-Ethyl-4-[({(1R,2R and 1S,2S)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexyl}-carbonyl)amino]-1H-pyrazole-3-carboxamide;
(1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(1,3,4-oxadiazol-2-yl)cyclohexanecarboxamide;
Trans(±)-(1R,2R and 1S,2S)—N-(3-Methyl-1,2-oxazol-5-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
Trans(±)-(1R,2R and 1S,2S)—N-(4-Methyl-1,3-oxazol-2-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
Trans(±)-(1R,2R and 1S,2S)—N-(5-Cyano-1-methyl-1H-pyrazol-4-yl)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
Trans(±)-(1R,2R and 1S,2S)—N-(3-Cyclopropyl-1,2,4-thiadiazol-5-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
Trans(±)-(1R,2R and 1S,2S)—N-(3-Methyl-1,2-thiazol-5-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide; and
Trans(±)-(1R,2R and 1 S,1 S)—N-(4-Cyano-3-methyl-1,2-thiazol-5-yl)-2-[4-(1H-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 18)

The method according to claim 18, wherein the compound is (1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(1-methyl-5-sulfamoyl-1H-pyrazol-4-yl)cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A method of treating diseases or conditions in which inhibition of FLAP is beneficial, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

### Claim at position 19

19-21. (canceled)
